Table 3.
Prognostic value of the leading symptoms in patients with diffuse glioma in group 1 by log-rank test.
| Leading Symptom | 1A (G 2–3) |
1B (G 4) |
Whole Group (G 2–4) |
||||||
|---|---|---|---|---|---|---|---|---|---|
| Prognosis (p) a | 95% CI for Mean Survival | Prognosis (p) a | 95% CI for Mean Survival | Prognosis (p) a | 95% CI for Mean Survival | ||||
| Lower | Upper | Lower | Upper | Lower | Upper | ||||
| Epileptic seizure | + (<0.001) [N.S./N.S.] |
1585 | 2245 | + (0.014) [+/N.S.] |
411 | 644 | + (<0.001) [+/+] |
996 | 1390 |
| Motor dysfunction | – (0.003) [N.S./N.S.] |
432 | 1027 | – (0.032) [–/N.S.] |
243 | 386 | – (<0.001) [–/N.S.] |
315 | 508 |
| Cognitive disorder | – (0.004) [–/N.S.] |
413 | 1075 | N.S. [N.S./N.S.] |
290 | 563 | – (<0.001) [–/N.S.] |
346 | 603 |
| Headache | N.S. [N.S./N.S.] |
599 | 2179 | N.S. [N.S./N.S.] |
336 | 668 | N.S. [N.S./N.S.] |
453 | 935 |
| Sensory symptom | N.S. [N.S./N.S.] |
1126 | 2065 | N.S. [N.S./N.S.] |
167 | 807 | N.S. [N.S./N.S.] |
433 | 1279 |
| Visual or other sense-impairing symptom | N.S. [N.S./N.S.] |
1158 | 3015 | N.S. [N.S./N.S.] |
277 | 389 | N.S. [N.S./N.S.] |
539 | 2076 |
| Tumor hemorrhage | N/A | N.S. [N.S./N.S.] |
38 | 589 | – (0.003) [–/N.S.] |
38 | 589 | ||
| Speech disorder | – (0.044) [–/N.S.] |
202 | 754 | N.S. [N.S./N.S.] |
123 | 1501 | N.S. [–/N.S.] |
157 | 1319 |
| Dizziness | N.S. [N.S./N.S.] |
66 | 954 | N.S. [N.S./N.S.] |
144 | 432 | – (0.028) [N.S./N.S.] |
186 | 491 |
+Predicts a better prognosis compared with other patients. – Predicts a worse prognosis compared with other patients. G, tumor grade; N/A, not available; N.S., no significant prognostic value.
a
Results reported separately for Tampere and Turku cohorts are shown individually in brackets.